Community Counts: Exploring Transcription Regulation & Immunotherapy for ES-SCLC: Tweetorial #1 Evaluation (ID: i805-4) Survey

Question Title

* 2. How many patients with ES-SCLC do you manage per week?

1 to 10

11 to 25

26 to 50

I am not directly involved in patient care

Question Title

* 3. Please select the option that best describes your practice setting.

Academic medical center

Community medical center

VA, DOD, or other government

Managed care

Research

Pharmaceutical industry

Question Title

* 4. After participating in this activity, how confident are you in the management of patients with ES-SCLC in your practice?

Very confident

Confident

Neutral

Little confidence

No confidence

Question Title

* 5. How committed are you to making changes in your practice based on your participation in this activity?

Very committed

Committed

Neutral

Not committed

I do not plan to make changes

If not committed or do not plan to make changes, please indicate reason

Question Title

* 6. Which of the following best describes the impact of this activity on your performance?

I gained new strategies/skills/information I can apply to my area of practice

I need more information before I can change my practice

My practice is already consistent with the information presented

This activity will not change my practice

Question Title

* 7. Which new strategies/skills/information will you apply to your area of practice? Please select all that apply.

Have a better understanding of patient subsets in which pembrolizumab and nivolumab are most beneficial

Carefully select patients for treatment with pembrolizumab and nivolumab

Consider PD-L1 testing in patients eligible for third-line therapy

Review of trial results prior to treatment selection

Review of guideline recommendation prior to treatment selection

Other (please specify)

Question Title

* 8. What barriers do you see to making changes in your practice? Please select all that apply. 

Lack of knowledge regarding evidence-based strategies

Lack of convincing evidence to warrant change

Lack of time/resources to consider change

Insurance, reimbursement or legal issues

Conflicting guidelines or evidence

Patient compliance and/or patient resource barriers

Other (please specify)

Question Title

* 9. Please rate your level of agreement by checking the appropriate rating.

After participating in today’s activity, I am now better able to:

	Strongly agree	Agree	Neutral	Disagree	Strongly disagree
Compare efficacy and safety data for new and emerging treatments for second-line extensive-stage-SCLC (ES-SCLC), as well for immunotherapies approved in subsequent lines	Compare efficacy and safety data for new and emerging treatments for second-line extensive-stage-SCLC (ES-SCLC), as well for immunotherapies approved in subsequent lines Strongly agree	Compare efficacy and safety data for new and emerging treatments for second-line extensive-stage-SCLC (ES-SCLC), as well for immunotherapies approved in subsequent lines Agree	Compare efficacy and safety data for new and emerging treatments for second-line extensive-stage-SCLC (ES-SCLC), as well for immunotherapies approved in subsequent lines Neutral	Compare efficacy and safety data for new and emerging treatments for second-line extensive-stage-SCLC (ES-SCLC), as well for immunotherapies approved in subsequent lines Disagree	Compare efficacy and safety data for new and emerging treatments for second-line extensive-stage-SCLC (ES-SCLC), as well for immunotherapies approved in subsequent lines Strongly disagree
Develop a plan of action for selecting appropriate treatment options for ES-SCLC patients who evidence disease progression during or after first-line chemotherapy	Develop a plan of action for selecting appropriate treatment options for ES-SCLC patients who evidence disease progression during or after first-line chemotherapy Strongly agree	Develop a plan of action for selecting appropriate treatment options for ES-SCLC patients who evidence disease progression during or after first-line chemotherapy Agree	Develop a plan of action for selecting appropriate treatment options for ES-SCLC patients who evidence disease progression during or after first-line chemotherapy Neutral	Develop a plan of action for selecting appropriate treatment options for ES-SCLC patients who evidence disease progression during or after first-line chemotherapy Disagree	Develop a plan of action for selecting appropriate treatment options for ES-SCLC patients who evidence disease progression during or after first-line chemotherapy Strongly disagree

Question Title

* 10. Please rate your level of agreement by checking the appropriate rating.

Narjust Duma, MD, effectively:

	Strongly agree	Agree	Neutral	Disagree	Strongly disagree
Presented the Material	Presented the Material Strongly agree	Presented the Material Agree	Presented the Material Neutral	Presented the Material Disagree	Presented the Material Strongly disagree
Avoided Commercial Bias	Avoided Commercial Bias Strongly agree	Avoided Commercial Bias Agree	Avoided Commercial Bias Neutral	Avoided Commercial Bias Disagree	Avoided Commercial Bias Strongly disagree

Question Title

* 11. Please rate your level of agreement by checking the appropriate rating.

Jacob M. Sands, MD, effectively:

	Strongly agree	Agree	Neutral	Disagree	Strongly disagree
Presented the Material	Presented the Material Strongly agree	Presented the Material Agree	Presented the Material Neutral	Presented the Material Disagree	Presented the Material Strongly disagree
Avoided Commercial Bias	Avoided Commercial Bias Strongly agree	Avoided Commercial Bias Agree	Avoided Commercial Bias Neutral	Avoided Commercial Bias Disagree	Avoided Commercial Bias Strongly disagree

Question Title

* 12. The content presented: 

	Strongly agree	Agree	Neutral	Disagree	Strongly disagree
Enhanced my current knowledge base	Enhanced my current knowledge base Strongly agree	Enhanced my current knowledge base Agree	Enhanced my current knowledge base Neutral	Enhanced my current knowledge base Disagree	Enhanced my current knowledge base Strongly disagree
Addressed my most pressing questions	Addressed my most pressing questions Strongly agree	Addressed my most pressing questions Agree	Addressed my most pressing questions Neutral	Addressed my most pressing questions Disagree	Addressed my most pressing questions Strongly disagree
Promoted improvements or quality in health care	Promoted improvements or quality in health care Strongly agree	Promoted improvements or quality in health care Agree	Promoted improvements or quality in health care Neutral	Promoted improvements or quality in health care Disagree	Promoted improvements or quality in health care Strongly disagree
Was scientifically rigorous and evidence based	Was scientifically rigorous and evidence based Strongly agree	Was scientifically rigorous and evidence based Agree	Was scientifically rigorous and evidence based Neutral	Was scientifically rigorous and evidence based Disagree	Was scientifically rigorous and evidence based Strongly disagree
Avoided commercial bias or influence	Avoided commercial bias or influence Strongly agree	Avoided commercial bias or influence Agree	Avoided commercial bias or influence Neutral	Avoided commercial bias or influence Disagree	Avoided commercial bias or influence Strongly disagree

Question Title

* 13. As a result of your participation in this activity, what is the one change you are most likely to implement in your practice?

Question Title

* 14. Please list any clinical issues/problems within your scope of practice you would like to see addressed in future educational activities for ES-SCLC:

Community Counts: Exploring Transcription Regulation & Immunotherapy for ES-SCLC: Tweetorial #1 Evaluation (ID: i805-4)

Question Title

* 1. How many years have you been in practice?

Question Title

* 2. How many patients with ES-SCLC do you manage per week?

Question Title

* 3. Please select the option that best describes your practice setting.

Question Title

* 4. After participating in this activity, how confident are you in the management of patients with ES-SCLC in your practice?

Question Title

* 5. How committed are you to making changes in your practice based on your participation in this activity?

Question Title

* 6. Which of the following best describes the impact of this activity on your performance?

Question Title

* 7. Which new strategies/skills/information will you apply to your area of practice? Please select all that apply.

Question Title

* 8. What barriers do you see to making changes in your practice? Please select all that apply.

Question Title

* 9. Please rate your level of agreement by checking the appropriate rating.

After participating in today’s activity, I am now better able to:

Question Title

* 10. Please rate your level of agreement by checking the appropriate rating.

Narjust Duma, MD, effectively:

Question Title

* 11. Please rate your level of agreement by checking the appropriate rating.

Jacob M. Sands, MD, effectively:

Question Title

* 12. The content presented:

Question Title

* 13. As a result of your participation in this activity, what is the one change you are most likely to implement in your practice?

Question Title

* 14. Please list any clinical issues/problems within your scope of practice you would like to see addressed in future educational activities for ES-SCLC:

Question Title

* 15. If you indicated that you perceived commercial bias or influence, please describe:

Question Title

* 1. How many years have you been in practice?

Question Title

* 2. How many patients with ES-SCLC do you manage per week?

Question Title

* 3. Please select the option that best describes your practice setting.

Question Title

* 4. After participating in this activity, how confident are you in the management of patients with ES-SCLC in your practice?

Question Title

* 5. How committed are you to making changes in your practice based on your participation in this activity?

Question Title

* 6. Which of the following best describes the impact of this activity on your performance?

Question Title

* 7. Which new strategies/skills/information will you apply to your area of practice? Please select all that apply.

Question Title

* 8. What barriers do you see to making changes in your practice? Please select all that apply.

Question Title

* 9. Please rate your level of agreement by checking the appropriate rating. After participating in today’s activity, I am now better able to:

Question Title

* 10. Please rate your level of agreement by checking the appropriate rating. Narjust Duma, MD, effectively:

Question Title

* 11. Please rate your level of agreement by checking the appropriate rating. Jacob M. Sands, MD, effectively:

Question Title

* 12. The content presented:

Question Title

* 13. As a result of your participation in this activity, what is the one change you are most likely to implement in your practice?

Question Title

* 14. Please list any clinical issues/problems within your scope of practice you would like to see addressed in future educational activities for ES-SCLC:

Question Title

* 15. If you indicated that you perceived commercial bias or influence, please describe:

* 8. What barriers do you see to making changes in your practice? Please select all that apply. 

* 9. Please rate your level of agreement by checking the appropriate rating.

After participating in today’s activity, I am now better able to:

* 10. Please rate your level of agreement by checking the appropriate rating.

Narjust Duma, MD, effectively:

* 11. Please rate your level of agreement by checking the appropriate rating.

Jacob M. Sands, MD, effectively:

* 12. The content presented: 